See the Aventi 340B Rebate Model Demo.
340B Rebate Model

Get ready for 340B rebate submissions in 2027.

HRSA has approved 10 manufacturers for the 340B rebate model starting January 1, 2027. Aventi prepares and submits your pharmacy and medical rebate claims to Beacon for every approved manufacturer.

One service for 2027 rebate claims, in-house pharmacy medical claims submissions to Beacon, and 340B ESP/Truzo claims data. Included for Aventi TPA clients.

Already an Aventi TPA client? Rebate submissions are included.See what's included

Learn more about in-house pharmacy medical claims submissions to Beacon.

See the 10 approved manufacturers.

  1. 1
    Purchase

    The covered entity buys the drug at a non-340B price instead of the 340B price.

  2. 2
    Submit

    Aventi prepares and submits pharmacy and medical rebate claims to Beacon, with claims data showing the drug qualified for 340B.

  3. 3
    Rebate

    Once the data is validated, the manufacturer pays the 340B discount back as a rebate.

For Aventi TPA clients

Already an Aventi TPA client? The rebate module is included.

If Aventi is already your 340B TPA, you don't need to buy a separate rebate tool or add another vendor for the 2027 rebate model. Rebate submissions run inside the same system of record that already qualifies your claims.

Included for Aventi TPA clients

  • 2027 340B rebate claim submissions to Beacon (pharmacy and medical, with conforming claim units)
  • In-house pharmacy medical claims submissions to Beacon (available now)
  • 340B ESP and Truzo claims data submissions
  • Rebate reconciliation: payments, short pays, denials and aging tracked against each submitted claim
  • Specialty pharmacy claims through our gateway with BioPlus, Accredo, Optum and many other specialty pharmacies

What you'll still do in Beacon

Your covered entity still completes Beacon enrollment: review Enrollment Status and provide bank details (including a certified bank letter), W9, and EIN/CP-575. Your Aventi account manager coaches you through it so rebates can pay out.

Not an Aventi TPA client? Rebate claim submission works even if Aventi isn't your TPA. Contact us for pricing. See pricing

HRSA-approved

HRSA-approved 2027 rebate model manufacturers

On October 1, 2026, HRSA approved 10 manufacturers for the 340B Rebate Model Pilot Program, covering 21 selected drugs. Rebates start January 1, 2027, and claims data is submitted through Beacon within 45 days of dispense.

AbbVie

AbbVie, Inc.

ImbruvicaLinzessVraylar
Platform
Beacon
Start
January 1, 2027

Amgen

Amgen, Inc.

EnbrelOtezlaOtezla XR
Platform
Beacon
Start
January 1, 2027

Astellas

Astellas Pharma US, Inc.

Xtandi
Platform
Beacon
Start
January 1, 2027

AstraZeneca

AstraZeneca Pharmaceuticals LP

Farxiga
Platform
Beacon
Start
January 1, 2027

Bristol Myers Squibb

Bristol Myers Squibb Company

EliquisPomalyst
Platform
Beacon
Start
January 1, 2027

Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc.

JardianceOfevTradjenta
Platform
Beacon
Start
January 1, 2027

GSK

GlaxoSmithKline (GSK)

Breo ElliptaTrelegy Ellipta
Platform
Beacon
Start
January 1, 2027

Merck

Merck Sharp & Dohme LLC

JanuviaJanumetJanumet XR
Platform
Beacon
Start
January 1, 2027

Pfizer

Pfizer Inc.

Ibrance
Platform
Beacon
Start
January 1, 2027

Teva

Teva Pharmaceuticals

AustedoAustedo XR
Platform
Beacon
Start
January 1, 2027

Last updated: October 2, 2026

Source: HRSA via AHA, Oct 1, 2026

Only these selected drugs move to rebates; all other drugs stay at upfront 340B pricing.

This is separate from the in-house pharmacy medical claims requirements tracker below.

Data updated 2026-10-02.
The basics

What is the 340B rebate model?

1

Purchase

The covered entity buys the drug at a non-340B price instead of the 340B price.

2

Submit

Aventi prepares and submits pharmacy and medical rebate claims to Beacon, with claims data showing the drug qualified for 340B.

3

Rebate

Once the data is validated, the manufacturer pays the 340B discount back as a rebate.

The rebate model changes when and how the 340B discount reaches you. It makes accurate, timely claims data central to getting paid.

Why now

Why covered entities need to be ready for 2027

On October 1, 2026, HRSA approved 10 manufacturers' plans for the 340B Rebate Model Pilot Program. The pilot starts January 1, 2027, and applies only to selected drugs for IPAY 2026/2027 on the CMS Medicare Drug Price Negotiation Selected Drug List.

Beacon, developed by Second Sight Solutions, already supports Medicare MFP validation and is now the IT platform for all 10 HRSA-approved rebate model plans, so rebate claims for every selected drug in the pilot flow through Beacon starting January 1, 2027.

Covered entities submit claims data through Beacon within 45 calendar days of dispense. Manufacturers must pay or deny within 10 calendar days of a completed submission.

The rebate equals WAC minus the 340B ceiling price on the date of dispense. Other drugs stay at upfront 340B pricing.

The rebate model doesn't replace 340B ESP or Kalderos TruZo. Only the selected drugs move to Beacon rebates, and covered entities still submit claims data to 340B ESP and Kalderos TruZo to meet other manufacturers' claims data requirements. Aventi's service covers those 340B ESP and TruZo submissions along with your rebate claims.

Reconciliation will not disappear under the rebate model. With a 45-day submission window and a 10-day pay-or-deny clock, covered entities already juggling multiple manufacturer portals, changing manufacturer requirements, staff capacity constraints and manual MTF claim downloads will need clean, submission-ready claims data and a way to track every rebate paid or denied.

How Aventi helps

How Aventi handles rebate submissions

Beacon-ready

Ready to submit pharmacy and medical rebate claims through Beacon’s Pharmacy Submissions and Medical Submissions workflows for the 2027 rebate model.

Conforming claim units

Submission-ready claims data matched to Beacon’s conforming-claim requirements, with real-time claim capture and precise eligibility matching.

340B ESP and Truzo (Kalderos)

Real-time 340B ESP integration and an API connection to Truzo, with automated ESP and TruZo submissions for both contract and in-house pharmacies.

Reconciliation and GFI tracking

Track rebates and monthly statements once claims clear, alongside Good Faith Inquiries, MFP reconciliation tools, negative balance management and duplicate discount monitoring.

One service, everything covered

One service covers rebate claims, in-house pharmacy medical claims submissions to Beacon, and 340B ESP/Truzo claims data.

Aventi also works with specialty pharmacies through exclusive integrations and a gateway with BioPlus, Accredo and Optum plus many other specialty pharmacies. Learn more for providers.

Pricing

One simple price

Included for Aventi TPA clients

Includes

  • 2027 340B rebate claim submissions
  • In-house pharmacy medical claims submissions to Beacon (available now)
  • 340B ESP and Truzo claims data submissions

Already an Aventi TPA client? All of this is included. The pricing above is for covered entities that use another TPA. See what's included

Manufacturer tracker

Manufacturers requiring in-house pharmacy claims data

A growing number of drug manufacturers now condition 340B pricing on claims data for drugs dispensed through a covered entity's own (in-house, entity-owned) pharmacy, not just contract pharmacies. The list below covers requirements we have verified against the manufacturer's published notice. Scope, covered products, state exemptions, and deadlines vary, so always review the full notice.

Last updated: October 1, 202616 manufacturers listed

Recent = effective on or after July 1, 2026.

Genentech

RecentAugust 31, 2026

Universal claims data: all CEs submit CLD for in-house pharmacy, outpatient facility, and CP dispenses/administrations via 340B ESP.

UCB

June 1, 2026

Hospital and grantee CEs with in-house pharmacies: all claim/dispensing data (pharmacy and medical) for 340B-priced drugs, entire portfolio, via 340B ESP within 45 days.

Bristol Myers Squibb

May 1, 2026

All CEs: CLD for all 340B utilization of listed drugs from entity-owned pharmacies and designated CPs, within 45 days.

Novo Nordisk

April 1, 2026

All CE types: claims-level data for all in-house pharmacy (and CP) 340B dispenses via 340B ESP within 45 days; annual in-house pharmacy certification.

Eli Lilly

February 1, 2026

All CE types: pharmacy and medical CLD for all 340B dispenses (incl. in-house), entire portfolio, via 340B ESP within 45 days (60 days for listed products).

CE = covered entity; CP = contract pharmacy; CLD = claims-level data; CH = consolidated health center; CAH/DSH/RRC/SCH = hospital covered entity types.

This tracker is for general information only and is not legal advice. Manufacturer policies change frequently; confirm requirements in each manufacturer's current notice.

Aventi handles in-house pharmacy medical claims submissions

Aventi handles in-house pharmacy medical claims submissions to Beacon and 340B ESP and monitors manufacturer requirement changes for you, even if Aventi isn't your TPA. Included for Aventi TPA clients; otherwise, contact us for pricing.

Or email Abi Romano directly at abi@aventihealth.com.

FAQ

340B rebate model questions

It is an approach where covered entities pay a non-340B price at purchase, submit claims data showing 340B eligibility, and receive the 340B discount afterward as a rebate, rather than receiving the discount up front.

The HRSA-approved 340B Rebate Model Pilot Program starts January 1, 2027. Covered entities must submit claims data to Beacon within 45 calendar days of dispense.

HRSA approved 10 manufacturers covering 21 selected drugs for a January 1, 2027 start through Beacon: AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer, Teva. Source: HRSA, October 1, 2026.

Yes. Aventi is Beacon-ready for pharmacy and medical rebate submissions, prepares claims to meet Beacon’s requirements, and coaches covered entities through enrollment. Aventi is built for HRSA's rebate model pilot and also integrates with 340B ESP and Truzo (Kalderos).

Covered entities still complete Beacon enrollment: review Enrollment Status and provide bank details (including a certified bank letter), W9, and EIN/CP-575. Aventi prepares and submits your claims and coaches you through enrollment so rebates can pay out.

Included for Aventi TPA clients: 2027 340B rebate claim submissions, current in-house pharmacy medical claims submissions to Beacon, and 340B ESP and Truzo claims data submissions. Using another TPA? Contact us for pricing.

Yes. If Aventi is your 340B TPA, 2027 rebate claim submissions to Beacon, in-house pharmacy medical claims submissions, 340B ESP and Truzo claims data submissions and rebate reconciliation are included. Using another TPA? Contact us for pricing.

No. Reconciliation will not disappear under the rebate model. Aventi tracks Good Faith Inquiries and provides MFP reconciliation tools in one view.

As of October 1, 2026, the following manufacturers require covered entities to submit 340B claims data for in-house (entity-owned) pharmacy dispenses, subject to each policy's scope and exemptions: Merck, Johnson & Johnson, Genentech, Boehringer Ingelheim, Novartis, GSK, Sobi, Sanofi, Amgen, Biogen, UCB, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Eli Lilly, Exelixis. Aventi handles in-house pharmacy medical claims submissions to Beacon and 340B ESP and monitors requirement changes, even if Aventi isn't your TPA. Included for Aventi TPA clients; otherwise, contact us for pricing.

Get your 340B program rebate-ready

Return to Aventi Health home.